2025-10-01 - Analysis Report
Okay, here's an analysis of Merck & Co. (MRK) based on the provided data, presented in English with a focus on key figures and insights.

**Report on Merck & Co. (MRK)**

**Company Overview:** Merck & Co. Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a wide range of healthcare solutions.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return (MRK):** -4.94%
*   **Cumulative Return (VOO):** 97.56%
*   **Return Disparity (MRK vs. VOO):** -102.50%

This indicates a significant underperformance of MRK compared to the S&P 500 over the period considered.

*   **Disparity Range:** Max: 26.7, Min: -80.0, Current: -79.9
*   **Relative Disparity:** 0.1

The relative disparity suggests that the current underperformance is near the worst levels observed historically within the provided data range.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD   | Alpha  | Beta | Cap(B) |
| :---------- | :------ | :---- | :----- | :--- | :----- |
| 2015-2017  | 1.0%    | 68.5% | -28.0% | 0.0  | 134.1  |
| 2016-2018  | 36.0%   | 69.8% | 21.0%  | -0.0 | 182.1  |
| 2017-2019  | 40.0%   | 69.8% | 18.0%  | 0.3  | 216.7  |
| 2018-2020  | 16.0%   | 79.6% | -8.0%  | 0.3  | 194.9  |
| 2019-2021  | 2.0%    | 79.6% | -44.0% | 0.7  | 191.4  |
| 2020-2022  | 15.0%   | 79.6% | 16.0%  | 0.7  | 277.0  |
| 2021-2023  | 33.0%   | 79.6% | 31.0%  | 0.3  | 272.2  |
| 2022-2024  | -4.0%   | 79.6% | -25.0% | 0.2  | 248.4  |
| 2023-2025  | -54.0%  | 71.5% | -116.0% | 1.6  | 200.2  |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) shows significant volatility. The recent negative CAGR of -54.0% for 2023-2025 is concerning.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high, indicating substantial potential for losses.
*   **Alpha:** The Alpha values fluctuate significantly, with some periods showing positive outperformance and others showing substantial underperformance relative to the benchmark. The recent Alpha of -116.0% is very negative.
*   **Beta:** The Beta values are generally low, suggesting that MRK has not historically moved in close correlation with the market.
*   **Cap(B):** The Market Cap data also exhibits volatility over the periods.

**2. Recent Price Action**

*   **Current Price:** 80.195
*   **Last Market Data:** {'price': 80.22, 'previousClose': 78.58, 'change': 2.09}
*   **5-day Moving Average:** 79.163
*   **20-day Moving Average:** 82.039
*   **60-day Moving Average:** 82.3822

**Analysis:**

The stock price closed at 80.195, with the last market update showing a recent increase. However, the current price is below both the 20-day and 60-day moving averages, which may suggest a short-term downtrend.

**3. Technical Indicators and Outlook**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 32.84 (Approaching Oversold)
*   **PPO:** -0.498
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (206 shares - Very Safe - MRI:0.90)
*   **Recent (20-day) Relative Disparity Change:** 0.1 (+) - Short-term upward movement.
*   **Expected Return (%):** -665.8% - This is a *very* negative long-term outlook.
*   **Last Market Change**: the 'change' of 2.09 (price increased from 'previousClose' of 78.58 to 'price' of 80.22) suggests a recent positive price movement.

**Analysis:**

Despite the recent price increase, the extremely negative expected return raises significant concerns about the long-term investment potential. The Hybrid Signal suggests a buying opportunity based on a high MRI score, but this should be carefully considered in light of the other data. The increase of 2.09 shows the change is big.

**4. Recent News & Significant Events**

*   **Positive Developments:**
    *   Merck's drug cuts the risk of high blood pressure worsening.
    *   Partnership with Variational AI to enhance drug development using AI.
    *   WINREVAIRâ„¢ reduces the risk of clinical worsening events in PAH patients.
*   **Potential Concerns:**
    *   Big Pharma's retreat due to NHS pricing pressures.
    *   Genmab to acquire cancer drug (potentially competitive pressure or missed opportunity for Merck).

**Analysis:**

The news is mixed. There are positive developments regarding drug efficacy and AI partnerships. However, concerns about pricing pressures and competitive dynamics exist.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.00)
*   **Target Price:** Avg: 101.60 / High: 141.00 / Low: 82.00
*   **Recent Rating Changes:** (No changes provided)

**Analysis:**

Analysts generally have a positive outlook on Merck, with a consensus rating of "Buy" and an average target price significantly above the current price.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue    |
| :---------- | :---- | :--------- |
| 2025-08-05 | 1.76 | 15.81 B$  |
| 2025-05-02 | 2.01 | 15.53 B$  |
| 2024-11-06 | 1.25 | 16.66 B$  |
| 2024-08-05 | 2.15 | 16.11 B$  |
| 2025-08-05 | 2.15 | 16.11 B$  |

**Analysis:**

*   Revenue has been fluctuating.
*   EPS is inconsistent.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
| :------------- | :--------- | :-------------- |
| 2025-06-30   | $15.81B   | 77.50%         |
| 2025-03-31   | $15.53B   | 77.98%         |
| 2024-12-31   | $15.62B   | 75.50%         |
| 2024-09-30   | $16.66B   | 75.51%         |
| 2024-06-30   | $16.11B   | 76.76%         |

**Capital and Profitability:**

| Quarter      | Equity     | ROE      |
| :------------- | :---------- | :------- |
| 2025-06-30   | $48.99B    | 9.04%   |
| 2025-03-31   | $48.34B    | 10.51%  |
| 2024-12-31   | $46.31B    | 8.08%   |
| 2024-09-30   | $44.50B    | 7.09%   |
| 2024-06-30   | $43.58B    | 12.52%  |

**Analysis:**

*   **Revenue and Profitability:** Revenue has shown some variability, but profit margins have remained relatively high and stable.
*   **Capital and Profitability:** Equity has generally increased over the observed period. ROE (Return on Equity) has fluctuated but remains generally positive.

**7. Overall Summary**

Merck (MRK) exhibits a mixed picture. The company has significantly underperformed the S&P 500, and the long-term expected return is extremely negative. Technical indicators are providing mixed signals. Recent news contains both positive and negative elements.

On the other hand, analyst consensus is positive, and the company demonstrates strong profit margins and growing equity.

**Recommendation:**

Given the conflicting signals, a cautious approach is warranted. The extremely negative expected return should be a major red flag. Further investigation is needed to understand the drivers behind the poor long-term outlook and the significant underperformance compared to the S&P 500. The analyst ratings and positive news should be viewed with caution, considering the other negative data points.
